Novavax, Inc.

US Government As Represented by the Secretary of the Army

Medigen, Inc.

The University of North Carolina at Chapel Hill

Emory University

The Uab Research Foundation

D4 Labs, LLC

Peter M Pushko

Gale Smith

Jonathan F Smith

Kutub Mahmood

Michael J Massare

Yingyun Wu

Rick Bright

Jinyou Zhang

Michael D Parker

Robin A Robinson

Ye Liu

Bin Zhou

Robert E Johnston

Nancy L Davis

George Ludwig

Igor Lukashevich

Irina Tretyakova

John S Lee

Alan L Schmaljohn

Thomas Kort

Michael C Hevey

Margaret Nathan

Robert G Ulrich

Susan L Welkos

Diane L Negley

Beatrice H Hahn

Richard W Compans

Leonard A Smith

Mary Kate Hart

Baozhong Wang

Julie A Wilson

Mark T Dertzbaugh

Bruce J Crise

David Craig Wright

Margret Nathan

Michael Bowe

Emily Wright

Weimin Liu

Bin Zhao

Diane I Negley

The present invention is generally related to modified or mutated respiratory syncytial virus fusion (F) proteins and methods for making and using them, including immunogenic compositions such as vaccines for the treatment and/or prevention of RSV infection.

Modified RSV F proteins and methods of their use

Described herein are Bovine immunodeficiency virus gag protein ('Bgag') recombinant virus like particles (“VLPs”) comprising one or more different types of target pathogen proteins. Also described, are compositions comprising the novel Bgag VLPs and the methods of making and using the novel Bgag VLPs.

Recombinant bovine immunodeficiency virus-like particles comprising an influenza HA transmembrane domain and C-terminus

Disclosed herein are adjuvanted protein vaccines comprising: a SARS-CoV-2 variant C.1.2 modified S1 Spike protein sequence and a non-phospholipid liposome, wherein the protein is encapsulated within the non-phospholipid liposome. The adjuvanted protein vaccines are suitable for subcutaneous administration. Also disclosed herein are modified spike protein sequences containing SARS-CoV-2 variant C.1.2 modified S1 Spike proteins and methods of use of the vaccines and sequences.

Adjuvanted vaccines containing modified S1 Spike protein of SARS-CoV-2 variant C.1.2 for subcutaneous administration and methods of use

Described herein, are Bovine immunodeficiency virus gag protein ('Bgag') recombinant virus like particles ('VLPs') including one or more different types of target pathogen proteins. Also described, are compositions including the Bgag VLPs and the methods of making and using the novel Bgag VLP.

Recombinant bovine immunodeficiency virus gag virus-like particles containing influenza immunogens

Compositions for protecting subjects from diseases caused by (+) SS RNA virus are described herein. The compositions include (i) a vector containing a DNA encoding a RNA molecule of an infectious (+) SS RNA virus operably linked to a eukaryotic RNA polymerase promoter and a carrier; or (ii) (+) SS RNA viruses obtained from eukaryotic cells transfected with the vector of (i) and a carrier.

Vaccines against infectious diseases caused by positive stranded RNA viruses

The present invention discloses and claims virus like particles (VLPs) that express and/or contains seasonal influenza virus proteins, avian influenza virus proteins and/or influenza virus proteins from viruses with pandemic potential. The invention includes vector constructs comprising said proteins, cells comprising said constructs, formulations and vaccines comprising VLPs of the inventions. The invention also includes methods of making and administrating VLPs to vertebrates, including methods of inducing substantial immunity to either seasonal and avian influenza, or at least one symptom thereof.

Functional influenza virus like particles (VLPs)

Described herein are iDNA vectors and vaccines and methods for using the same. The iDNA generates live attenuated vaccines in eukaryotic cells in vitro or in vivo for pathogenic RNA viruses, particularly yellow fever virus and Venezuelan equine encephalitis virus. When iDNA is injected into the vaccine recipient, RNA of live attenuated virus is generated by in vivo transcription in the recipient's tissues. This initiates production of progeny attenuated viruses in the tissues of the vaccine recipient, as well as elicitation of an effective immune response protecting against wild-type, non-attenuated virus.

iDNA vaccines and methods for using the same

Functional influenza virus-like particles (VLPS)

This invention discloses a method of increasing production of virus-like particles comprising expressing an avian influenza matrix protein. The invention also comprises methods of making and using said VLPs.

Highly efficient influenza matrix (M1) proteins

IDNA vaccines and methods for using the same

Recombinant influenza virus proteins, including influenza capsomers, subviral particles, virus-like particles (VLP), VLP complexes, and/or any portions of thereof, are provided as a vaccine for influenza viruses. The invention is based on the combination of two vaccine technologies: (1) intrinsically safe recombinant vaccine technology, and (2) highly immunogenic, self-assembled protein macromolecules embedded in plasma membranes and comprised of multiple copies of influenza virus structural proteins exhibiting neutralizing epitopes in native conformations. More specifically, this invention relates to the design and production of functional homotypic and heterotypic recombinant influenza virus-like particles (VLPs) comprised of recombinant structural proteins of human influenza virus type A/Sydney/5/94 (H3N2) and/or avian influenza virus type A/Hong Kong/1073/99 (H9N2) in baculovirus-infected insect cells and their application as a vaccine in the prevention of influenza infections and as a laboratory reagent for virus structural studies and clinical diagnostics.

Functional influenza virus-like particles (VLPs)

Growing community of inventors

Frederick, MD, United States of America

Peter M Pushko